This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures

This study has been completed.
Information provided by:
Novalar Pharmaceuticals, Inc. Identifier:
First received: March 30, 2006
Last updated: November 16, 2006
Last verified: November 2006
This Phase 3 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the efficacy, pharmacodynamics, and safety of NV-101 administered as a submucosal injection following completion of a restorative or periodontal maintenance procedure requiring local anesthesia with an agent containing a vasoconstrictor. Local vasodilatation that results in more rapid clearance of the anesthetic is the proposed mechanism of action.

Condition Intervention Phase
Anesthesia, Dental Drug: Phentolamine Mesylate (NV-101) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Maxillary Procedures

Resource links provided by NLM:

Further study details as provided by Novalar Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • to determine if NV-101 accelerates time to normal sensation of the upper lip compared to control, as measured by standardized palpation procedure

Secondary Outcome Measures:
  • to determine if NV-101 accelerates the time to STAR-7 score of zero, as measured by soft tissue anesthesia questionnaire
  • to determine if NV-101 accelerates the time to normal function, as measured by a functional assessment battery
  • to determine if NV-101 accelerates the time to normal sensation of the tongue, as measured by standardized palpation procedure
  • to characterize the pharmacodynamic profile of NV-101, as measured by onset and offset of treatment effect
  • to evaluate the safety and tolerability of NV-101

Estimated Enrollment: 240
Study Start Date: February 2006
Estimated Study Completion Date: July 2006

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female greater than or equal to 12 years
  • Sufficiently healthy, as determined by the Investigator, to receive routine dental care
  • Requires a restorative procedure in the maxilla such as cavity preparation, restoration/filling, or crown or a periodontal maintenance procedure, such as teeth cleaning (non-surgical scaling and/or root planing) on the same side of the upper mouth
  • Requires one or two cartridges of local anesthesia administered by one of the following intraoral injection techniques:

    • inferior alveolar nerve block;
    • Gow-Gates nerve block;
    • Vazirani-Akinosi block;
    • mental-incisive block; or
    • supraperiosteal injection.
  • Dental procedure is completed within 60 minutes of the first administration of local anesthetic
  • Normal upper lip sensations at baseline prior to administration of local anesthetic
  • Upper lip on the side of the procedure is numb (no feeling) at the completion of the dental procedure
  • Soft tissue anesthesia recovery score of zero prior to anesthetic
  • Functional Assessment Battery by subject and observer rating is normal prior to anesthetic
  • Negative urine pregnancy test at screening in all females of childbearing potential past menarche (includes all females except for those whose menstrual periods have not occured for greater than or equal to 1 year after menopause, who are surgically sterilized, or who had a hysterectomy)
  • Understands and gives written informed consent
  • Subjects 12 to 17 years of age give written assent and parent(s) or legal guardian(s) give written informed consent
  • Can communicate with the Investigator and study staff, and can understand and comply with the requirements of the protocol

Exclusion Criteria:

  • History or presence of any condition that contraindicates routine dental care
  • Requires more than two cartridges of local anesthetic (excluding supplemental injections) or use of nitrous oxide or sedatives to perform the scheduled dental procedure
  • Scheduled dental procedure takes greater than 60 minutes to complete
  • Unable to tolerate 1 liter of water over 5 hours
  • Concurrent conditions: any incapacitating medical condition (e.g. unstable angina, uncontrolled cardiac arrhythmias, uncontrolled hypertension, uncontrolled hyperthyroidism); significant infection or inflammatory process of the oral cavity.
  • Concomitant medications: use of an opioid or opioid-like analgesic (e.g. codeine, tramadol, pentazocine) within 24 hours prior to administration of anesthetic
  • Allergy or intolerance to lidocaine, articaine, prilocaine, mepivacaine, epinephrine, levonordefrin, sulfites, phentolamine, or topical benzocaine
  • Has used an investigational drug and/or participated in any clinical study within 30 days of study drug administration
  • Has participated in this study or any previous study of phentolamine mesylate for reversal of local soft tissue anesthesia (STA)
  • Any condition which, in the opinion of the Investigator, increases the risk to the subject of participating in this study or decreases the likelihood of compliance with the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00309335

United States, Massachusetts
Tufts University School of Dental Medicine
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
Novalar Pharmaceuticals, Inc.
Principal Investigator: Athena Papas, DMD Tufts University School of Dental Medicine
  More Information Identifier: NCT00309335     History of Changes
Other Study ID Numbers: NOVA 04-200
Study First Received: March 30, 2006
Last Updated: November 16, 2006

Keywords provided by Novalar Pharmaceuticals, Inc.:
Soft Tissue Anesthesia (Numbness)

Additional relevant MeSH terms:
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents processed this record on September 20, 2017